Anti-coagulant treatment for atrial fibrillation does not worsen outcomes for patients with kidney disease

Although some research has suggested that the use of the anticoagulant warfarin for atrial fibrillation among patients with chronic kidney disease would increase the risk of death or stroke, a study that included more than 24,000 patients found a lower l-year risk of the combined outcomes of death, heart attack or stroke without a higher risk of bleeding, according to a study in JAMA. Juan Jesus Carrero, Ph.D.